FDA Approves Sanofi's Hemophilia Drug
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
GlobalData on MSN9h
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
PharmExec6h
FDA Approves Sanofi’s Qfitlia for Prophylaxis in Patients with Hemophilia A or B
Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...
BioSpace10h
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
PMLive12h
Sanofi’s Qfitlia granted FDA approval to treat haemophilia A or B
Sanofi’s Qfitlia (fitusiran) has been approved by the US Food and Drug Administration (FDA) as the first therapy to treat ...
Pharmabiz20h
US FDA approves Sanofi’s Qfitlia to treat haemophilia A or B, with or without factor inhibitors
Silver Spring, Maryland Monday, March 31, 2025, 09:00 Hrs [IST] ...
The Pharma Letter14h
Qfitlia scores a first with FDA approval
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for ...
Clinical Advisor10h
Chlamydia Vaccine Candidate Gets Fast Track Status
The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.
PharmiWeb14h
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
The US Food and Drug Administration (FDA) has approved Qfitlia (fitusiran), the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes ...
360Dx10h
Siemens Healthineers Gains FDA 510(k) Clearance for Blood Clot Drug CDx
The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.
GEN - Genetic Engineering and Biotechnology News9h
RNAi Therapeutic for Hemophilia A or B Gets FDA Approval
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
PMLive12h
PMLiVE’s Top Pharma list – results and predictions for global drug sales
The list ranks the top companies in the pharmaceutical industry by their global sales, as well as by their revenues in the US ...